Company news
Vertex Pharmaceuticals Incorporated news in 2021
Vertex Pharmaceuticals Incorporated's news releases, calls and decks from 2021, newest first.
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
November 30, 2021
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
November 18, 2021
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
November 11, 2021
Vertex Reports Third-Quarter 2021 Financial Results
November 1, 2021
Vertex's Supplement to a New Drug Submission for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Patients Ages 6-11 Accepted for Priority Review by Health Canada
October 27, 2021
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
October 25, 2021
Vertex to Announce Third-Quarter 2021 Financial Results on November 2
October 21, 2021
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
October 18, 2021
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
October 17, 2021
Vertex's Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
September 22, 2021
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA®(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
September 17, 2021
Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th
September 12, 2021
Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis
August 25, 2021
Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
August 25, 2021
Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
August 23, 2021
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
August 3, 2021
Vertex Reports Second-Quarter 2021 Financial Results
July 28, 2021
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
July 27, 2021
Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
July 18, 2021
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
July 15, 2021
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients
June 27, 2021
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis
June 24, 2021
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
June 18, 2021
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
June 17, 2021
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
June 10, 2021
Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency
June 9, 2021
CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
June 8, 2021
Vertex Reports First-Quarter 2021 Financial Results
April 28, 2021
Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene
April 27, 2021
Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development
April 25, 2021
Vertex to Announce First-Quarter 2021 Financial Results on April 29
April 18, 2021
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
March 25, 2021
Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
March 23, 2021
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
March 9, 2021
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
January 31, 2021
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
January 27, 2021
Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
January 25, 2021
Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
January 21, 2021
Calls in 2021
- Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2021 Earnings Call
Nov 2, 2021
Transcript - Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2021 Earnings Call
Jul 29, 2021
Transcript - Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2021 Earnings Call
Apr 29, 2021
Transcript - Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2020 Earnings Call
Feb 1, 2021
Transcript